Cover Image
市場調查報告書

Actinium Pharmaceuticals, Inc.的產品平台分析

Actinium Pharmaceuticals, Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 256032
出版日期 內容資訊 英文 45 Pages
訂單完成後即時交付
價格
Back to Top
Actinium Pharmaceuticals, Inc.的產品平台分析 Actinium Pharmaceuticals, Inc. - Product Pipeline Review - 2016
出版日期: 2016年08月24日 內容資訊: 英文 45 Pages
簡介

Actinium Pharmaceuticals, Inc.是總公司設立在美國生物製藥企業,著重於α射線放出抗體為中心的癌症治療藥的開發。

本報告提供Actinium Pharmaceuticals, Inc. 的治療藥開發平台的現狀及各開發階段比較分析、各藥物標靶、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

Actinium Pharmaceuticals, Inc. 的基本資料

  • Actinium Pharmaceuticals, Inc. 概要
  • 主要資訊
  • 企業資料

Actinium Pharmaceuticals, Inc. :R&D概要

  • 主要的治療範圍

Actinium Pharmaceuticals, Inc. :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Actinium Pharmaceuticals, Inc. :開發中產品概況

  • 後期階段產品開發中產品
    • 第三階段的產品/聯合治療模式
  • 在臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Actinium Pharmaceuticals, Inc. :藥物簡介

  • Iomab-B
  • HuM195-Ac-225
  • AAA-225
  • Actimab-B
  • Actimab-Br
  • Actimab-C
  • Actimab-P
  • Monoclonal Antibody Conjugate for Cancer

Actinium Pharmaceuticals, Inc. :開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Actinium Pharmaceuticals, Inc. :最近的開發平台資訊

Actinium Pharmaceuticals, Inc. :開發中止的開發中產品

  • 開發中止的開發中產品

Actinium Pharmaceuticals, Inc. :總公司和子公司的所在地

  • 總公司
  • 其他分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08122CDB

Summary

Global Markets Direct's, 'Actinium Pharmaceuticals, Inc. - Product Pipeline Review - 2016', provides an overview of the Actinium Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Actinium Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Actinium Pharmaceuticals, Inc.
  • The report provides overview of Actinium Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Actinium Pharmaceuticals, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Actinium Pharmaceuticals, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Actinium Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Actinium Pharmaceuticals, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Actinium Pharmaceuticals, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Actinium Pharmaceuticals, Inc. Snapshot
    • Actinium Pharmaceuticals, Inc. Overview
    • Key Information
    • Key Facts
  • Actinium Pharmaceuticals, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Actinium Pharmaceuticals, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Actinium Pharmaceuticals, Inc. - Pipeline Products Glance
    • Actinium Pharmaceuticals, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Actinium Pharmaceuticals, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Actinium Pharmaceuticals, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Actinium Pharmaceuticals, Inc. - Drug Profiles
    • Iomab-B
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Actimab-A
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BC-8Y90
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BC-8SA
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Actimab-B
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Actimab-Br
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Actimab-C
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Actimab-P
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate for Hematological Tumor and Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate for Oncology
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Actinium Pharmaceuticals, Inc. - Pipeline Analysis
    • Actinium Pharmaceuticals, Inc. - Pipeline Products by Target
    • Actinium Pharmaceuticals, Inc. - Pipeline Products by Route of Administration
    • Actinium Pharmaceuticals, Inc. - Pipeline Products by Molecule Type
    • Actinium Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action
  • Actinium Pharmaceuticals, Inc. - Recent Pipeline Updates
  • Actinium Pharmaceuticals, Inc. - Dormant Projects
  • Actinium Pharmaceuticals, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • Bismab-A
  • Actinium Pharmaceuticals, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Actinium Pharmaceuticals, Inc., Key Information
  • Actinium Pharmaceuticals, Inc., Key Facts
  • Actinium Pharmaceuticals, Inc. - Pipeline by Indication, 2016
  • Actinium Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • Actinium Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • Actinium Pharmaceuticals, Inc. - Phase III, 2016
  • Actinium Pharmaceuticals, Inc. - Phase II, 2016
  • Actinium Pharmaceuticals, Inc. - Phase I, 2016
  • Actinium Pharmaceuticals, Inc. - Preclinical, 2016
  • Actinium Pharmaceuticals, Inc. - Pipeline by Target, 2016
  • Actinium Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • Actinium Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • Actinium Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
  • Actinium Pharmaceuticals, Inc. - Recent Pipeline Updates, 2016
  • Actinium Pharmaceuticals, Inc. - Dormant Developmental Projects,2016
  • Actinium Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2016

List of Figures

  • Actinium Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2016
  • Actinium Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2016
  • Actinium Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2016
  • Actinium Pharmaceuticals, Inc. - Pipeline by Target, 2016
  • Actinium Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2016
  • Actinium Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2016
  • Actinium Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2016
Back to Top